Anavex Life Sciences Corp (AVXL)

[falconer66a]

CMT (Charcot–Marie–Tooth disease ), much in the manner of multiple sclerosis, is caused by deterioration of the myelin sheath, the protein insulation around neurons. With an adequate myelin sheath, nerve impulses travel normally along nerves. With deterioration or weakening of the myelin sheath, nerve impulses are lost or disrupted. Hence, the severe muscular and other symptoms.

Might blarcamesine (Anavex 2-73) be therapeutic? Such has been the question for multiple sclerosis. Clinical trials in humans will have to decide the question; probably sometime in the future.

The viability of blarcamesine against multiple sclerosis has, for some time, been a matter of interest. As I recall, previously MS was listed as a target disease on the Anavex website. But not in recent periods. But (am I not correct on this?) MS appeared in the new blarcamesine patent just issued to Anavex Life Sciences Corp? If the drug can maintain or restore the degraded myelin of nerves with multiple sclerosis, good chance, at least to some degree, it could do that for individuals with Charcot–Marie–Tooth disease.